Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 9, 2024
Daily News
January 9, 2024
- BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
January 9, 2024
- FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
- Organon Japan Gets Approval for Fertility Med Follistim after Re-Filing
January 9, 2024
- Trelegy Frontrunner in GP Promotion, Dayvigo Defends Title in HP List in October: Intage
January 9, 2024
- Boehringer Grabs Rights to Kyowa Kirin’s Fibro-Inflammatory Disease Drug
January 9, 2024
- US FDA Accepts Stelara Biosimilar for Review: Meiji
January 9, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…